189 related articles for article (PubMed ID: 33861419)
1. Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model.
Gaba RC; Khabbaz RC; Muchiri RN; Morrison JD; Elkhadragy L; Totura WM; Samuelson JP; Whiteley HE; Deaton RL; Nguyen PL; Sverdlov M; Johnson JJ; van Breemen RB; Lokken RP
Drug Deliv Transl Res; 2022 May; 12(5):1105-1117. PubMed ID: 33861419
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Early Tumor Response to Conventional Transarterial Chemoembolization with Sorafenib and Doxorubicin in a VX2 Rabbit Tumor Model.
Elkhadragy L; Khabbaz RC; Muchiri RN; Totura WM; Samuelson JP; Whiteley HE; van Breemen RB; Lokken RP; Gaba RC
J Vasc Interv Radiol; 2022 Oct; 33(10):1213-1221.e5. PubMed ID: 35850455
[TBL] [Abstract][Full Text] [Related]
3. Correlation of Doxorubicin Delivery and Tumor Necrosis after Drug-eluting Bead Transarterial Chemoembolization of Rabbit VX2 Liver Tumors.
Gaba RC; Emmadi R; Parvinian A; Casadaban LC
Radiology; 2016 Sep; 280(3):752-61. PubMed ID: 26967144
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies.
Savic LJ; Chapiro J; Funai E; Bousabarah K; Schobert IT; Isufi E; Geschwind JH; Stark S; He P; Rudek MA; Perez Lozada JC; Ayyagari R; Pollak J; Schlachter T
Eur Radiol; 2021 May; 31(5):3002-3014. PubMed ID: 33063185
[TBL] [Abstract][Full Text] [Related]
5. Comparison of drug release and pharmacokinetics after transarterial chemoembolization using diverse lipiodol emulsions and drug-eluting beads.
Choi JW; Cho HJ; Park JH; Baek SY; Chung JW; Kim DD; Kim HC
PLoS One; 2014; 9(12):e115898. PubMed ID: 25551760
[TBL] [Abstract][Full Text] [Related]
6. Mapping Drug Dose Distribution on CT Images Following Transarterial Chemoembolization with Radiopaque Drug-Eluting Beads in a Rabbit Tumor Model.
Mikhail AS; Pritchard WF; Negussie AH; Krishnasamy VP; Amchin DB; Thompson JG; Wakim PG; Woods D; Bakhutashvili I; Esparza-Trujillo JA; Karanian JW; Willis SL; Lewis AL; Levy EB; Wood BJ
Radiology; 2018 Nov; 289(2):396-404. PubMed ID: 30106347
[TBL] [Abstract][Full Text] [Related]
7. Chemoembolization of liver cancer with doxorubicin-loaded CalliSpheres microspheres: plasma pharmacokinetics, intratumoral drug concentration, and tumor necrosis in a rabbit model.
Liang B; Zhao D; Liu Y; Guo X; Zhang H; Zhang L; Zheng C
Drug Deliv Transl Res; 2020 Feb; 10(1):185-191. PubMed ID: 31482517
[TBL] [Abstract][Full Text] [Related]
8. Development and evaluation of an ultrasound-triggered microbubble combined transarterial chemoembolization (TACE) formulation on rabbit VX2 liver cancer model.
Kim D; Lee JH; Moon H; Seo M; Han H; Yoo H; Seo H; Lee J; Hong S; Kim P; Lee HJ; Chung JW; Kim H
Theranostics; 2021; 11(1):79-92. PubMed ID: 33391462
[TBL] [Abstract][Full Text] [Related]
9. Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer.
Liu L; Liang X; Xu X; Zhang X; Wen J; Chen K; Su X; Teng Z; Lu G; Xu J
Acta Biomater; 2021 Aug; 130():374-384. PubMed ID: 34082098
[TBL] [Abstract][Full Text] [Related]
10. Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model.
Doemel LA; Santana JG; Savic LJ; Gaupp FML; Borde T; Petukhova-Greenstein A; Kucukkaya AS; Schobert IT; Hamm CA; Gebauer B; Walsh JJ; Rexha I; Hyder F; Lin M; Madoff DC; Schlachter T; Chapiro J; Coman D
Eur Radiol; 2022 Apr; 32(4):2437-2447. PubMed ID: 34718844
[TBL] [Abstract][Full Text] [Related]
11. Periodic mesoporous organosilica-coated magnetite nanoparticles combined with lipiodol for transcatheter arterial chemoembolization to inhibit the progression of liver cancer.
Liu L; Xu X; Liang X; Zhang X; Wen J; Chen K; Su X; Ma Y; Teng Z; Lu G; Xu J
J Colloid Interface Sci; 2021 Jun; 591():211-220. PubMed ID: 33609893
[TBL] [Abstract][Full Text] [Related]
12. Sulfamethazine-based pH-sensitive hydrogels with potential application for transcatheter arterial chemoembolization therapy.
Lym JS; Nguyen QV; Ahn da W; Huynh CT; Jae HJ; Kim YI; Lee DS
Acta Biomater; 2016 Sep; 41():253-63. PubMed ID: 27184404
[TBL] [Abstract][Full Text] [Related]
13. Transcatheter arterial chemoembolization (TACE) with iRGD peptide in rabbit VX2 liver tumor.
Liu X; Xie Y; Qi X; Xu K
J Cancer Res Ther; 2020; 16(7):1703-1709. PubMed ID: 33565520
[TBL] [Abstract][Full Text] [Related]
14. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
15. Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model.
Berz AM; Santana JG; Iseke S; Gross M; Pekurovsky V; Laage Gaupp F; Savic LJ; Borde T; Gottwald LA; Boustani AM; Gebauer B; Lin M; Zhang X; Schlachter T; Madoff DC; Chapiro J
J Vasc Interv Radiol; 2022 Jul; 33(7):764-774.e4. PubMed ID: 35346859
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.
Parvinian A; Casadaban LC; Hauck ZZ; van Breemen RB; Gaba RC
Diagn Interv Radiol; 2015; 21(3):235-40. PubMed ID: 25835078
[TBL] [Abstract][Full Text] [Related]
17. Drug-Eluting Embolic Loaded with Tyrosine Kinase Inhibitor Targeted Therapies for Transarterial Chemoembolization in a VX2 Model.
Abi-Jaoudeh N; Sadeghi B; Javan H; Na J; Beaton G; Tucci F; Ravula S; Imagawa DK
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370846
[TBL] [Abstract][Full Text] [Related]
18. Drug-Eluting Microsphere Versus Cisplatin-Based Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma: Propensity Score-Matched Analysis.
Chu HH; Gwon DI; Kim JH; Ko GY; Shin JH; Yoon HK
AJR Am J Roentgenol; 2020 Sep; 215(3):745-752. PubMed ID: 32569514
[No Abstract] [Full Text] [Related]
19. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Wu X; Chapiro J; Malhotra A; Kothary N
J Vasc Interv Radiol; 2021 Jan; 32(1):2-12.e1. PubMed ID: 33160827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
